Forget about Vivagel, and the FDA, and Viraleze, and India, and the TGA, and condom coatings. Management are not pushing SPL7013 any more, and with the demise of a treatment for conjunctivitis I think the best thing to do is sell it all off to the highest bidder. Whether the company receives an offer that covers it’s outlay over the years is a mute point, but they can concentrate on DEP, which in itself is not a one trick pony.
So, what do I want?
Phase 2 results and proof of concept!
When do I want it?
Now!
Ann: Starpharma receives $7.7M R&D tax incentive refund, page-12
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
